NASDAQ$GOCO
GoHealth Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
GoHealth Inc reported sharply lower revenues and a significant net loss for Q1 2026 amid reduced Medicare Advantage activities.
GoHealth scaled back Medicare Advantage operations in response to tightening health plan economics, resulting in net revenues of $11.9 million compared to $221.0 million in the prior year. The company recorded a net loss of $66.1 million and negative Adjusted EBITDA of $22.2 million while focusing on cost reductions and GoHealth Protect. Management expressed substantial doubt about the company's ability to continue as a going concern due to liquidity covenant concerns.
- Net revenues declined 94.6% year-over-year to $11.9 million due to intentional reduction in Medicare Advantage submissions.
- Net loss widened to $66.1 million with operating loss of $34.8 million and interest expense of $30.8 million.
- Submissions fell to 18,615 while Sales per Submission decreased to $621 and Direct Operating Cost per Submission rose to $942.
- Company is exploring strategic alternatives with lenders amid going concern uncertainty and minimum liquidity covenant risks.
Headline financials
Revenue & EPS history
GoHealth · Revenue · Quarterly
$11.9M
Revenue by segment
GoHealth · $11.9M total across 4 segments · Q1 2026
- Medicare Agency Revenue$9.8M—82.2%
- Other Non-Agency Revenue$1.76M—14.8%
- Medicare Non-Agency Revenue$200K—1.7%
- Other Agency Revenue$155K—1.3%
Forward guidance
Company is engaged in discussions with lenders regarding strategic alternatives including potential change of control or restructuring while implementing cost savings initiatives.
Headwinds
- Substantial doubt about ability to continue as going concern
- Probable inability to maintain liquidity covenant within next twelve months
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
-7.7%
Avg return
Earnings day
-9.0%
Avg return
5 days after
-6.6%
Avg return
30 days after
26%
6 / 23 earnings
Positive
+32.2%
Q1 2023
Best reaction
-45.5%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.5% | — | — | |
| Q3 2025 | -24.4% | -32.0% | -12.8% | |
| Q2 2025 | -9.0% | -7.6% | -23.8% | |
| Q1 2025 | -0.6% | -17.4% | -21.4% | |
| Q4 2024 | -14.4% | -14.9% | -32.8% | |
| Q3 2024 | -6.6% | -0.4% | -15.4% | |
| Q2 2024 | -21.4% | -28.3% | -34.0% | |
| Q1 2024 | -8.0% | -11.1% | +2.2% | |
| Q4 2023 | -13.0% | -25.7% | -27.0% | |
| Q3 2023 | +2.3% | +6.7% | +7.4% | |
| Q2 2023 | +6.8% | +6.3% | -17.2% | |
| Q1 2023 | +32.2% | +44.8% | +99.5% | |
| Q4 2022 | -19.9% | -6.2% | -18.5% | |
| Q3 2022 | -16.7% | -9.4% | +95.3% | |
| Q2 2022 | -31.5% | -43.3% | -57.0% | |
| Q1 2022 | +11.1% | +4.9% | +6.5% | |
| Q4 2021 | +23.7% | +37.7% | -9.8% | |
| Q3 2021 | +1.1% | -4.7% | -18.1% | |
| Q2 2021 | -45.5% | -42.2% | -34.7% | |
| Q1 2021 | -2.7% | -5.6% | -4.0% | |
| Q4 2020 | -14.9% | -16.9% | -4.1% | |
| Q3 2020 | -14.9% | -15.1% | +1.8% | |
| Q2 2020 | -10.5% | -18.5% | -27.1% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro